Clinical Trials Logo

Clinical Trial Summary

Ovarian endometriosis (endometrioma) can be a cause of subfertility. According to European Society of Human Reproduction and Embryology (ESHRE) guidelines, surgery for endometrioma is recommended when an endometrioma is more than 3 cm in diameter because this management is associated with better spontaneous conception rates. Nevertheless, surgery can also be potentially associated with a risk of destruction of functional ovarian tissue and reduction in ovarian reserve.

Anti-müllerian hormone (AMH) is a member of the Transforming Growth Factor beta family and is expressed by the small (<8 mm) pre-antral and early antral follicles. The AMH level reflects the size of the primordial follicle pool, and may be the best biochemical marker of ovarian function across an array of clinical situations Its level in serum is almost stable between 20 and 35 years of the woman´s life, unless using hormonal contraception and / or they suffer with Polycystic ovarian syndrome (PCOS). The level of AMH is also a useful indicator for the prediction chances of success of spontaneous or assisted conceptions. However, there paucity of data regarding changes in serum levels of AMH following surgery for endometrioma.

An alternative way for estimating ovarian reserve is quantifying ovarian mass with using standard 3D transvaginal ultrasound calculation (OVM) and assessment of antral follicular count.

The gold standard of endometrioma surgery is laparoscopic excision with suture or gentle coagulation of the rest of ovary or by the use of laparoscopic treatment with argon plasma energy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04452123
Study type Interventional
Source Charles University, Czech Republic
Contact Jan Humplik, MD
Phone 420377105254
Email humplikj@fnplzen.cz
Status Not yet recruiting
Phase N/A
Start date July 1, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT01268930 - Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas N/A
Completed NCT05323539 - Comparison of Thyroid Volumes in Patients With and Without Endometrioma N/A
Recruiting NCT04178876 - Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS) N/A
Completed NCT06421857 - Hemostatic Measures During Laparoscopic Cystectomy for Endometrioma N/A
Recruiting NCT04151433 - Conservative Endometrioma Surgery N/A
Completed NCT01942122 - DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis Phase 2/Phase 3
Withdrawn NCT00999479 - Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation N/A
Recruiting NCT03687398 - Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls
Not yet recruiting NCT06377553 - PET/MRI for Evaluation of Endometriosis
Not yet recruiting NCT03788720 - Suture of the Ovary After Enucleation of Ovarian Endometrioma N/A
Completed NCT01982526 - Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients
Recruiting NCT05962775 - Ethanol Sclerotherapy Prior to ART N/A
Completed NCT03484546 - Optimum Menstrual Cycle Time for Endometrioma Excision
Completed NCT01808170 - Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve N/A
Recruiting NCT05637073 - Effect of Management of the Endometrioma on Ovarian Reserve
Completed NCT06219044 - Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization N/A
Recruiting NCT03620838 - Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)
Terminated NCT03571776 - Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial N/A
Enrolling by invitation NCT02472873 - Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas N/A
Completed NCT04941833 - Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo Phase 2/Phase 3